Copeptin in Normal- to Hyperosmolar States

University Hospital, Basel, Switzerland90 enrolled

Overview

Kinetics of Copeptin in response to osmotic alterations in healthy volunteers

Construction of the standard area of copeptin release in the normo- and hyperosmolar state and its half-life based on ist decline during hypoosmotic Suppression in healthy volunteers.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Copeptin Blood Values

Interventions

Hypertonic saline infusionOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Minimum Age 18 * no severe comorbidities * no medication (except contraceptives) * baseline sodium Level 135-145mmol/l * euvolemic status Exclusion Criteria: * history of heart failure * liver cirrhosis * kidney disease (GFR \<60ml/min) * anemia * uncontrolled Hypertension * pregnancy * Diabetes mellitus * BMI \>28kg/m2 * other severe disease

Locations (2)

University Hospital Würzburg

Würzburg, Germany

University hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

Physiological relationship between Serum osmolality and Plasma copeptin release.

Copeptin and Blood osmolality will be measured concomitantly while hypertonic saline is infused. The infusion is continued until a hyperosmolar state is reached (defined with a sodium-level of 150mmol/l). Definition of an area of normality describing the physiological relationship between Serum osmolality and Plasma copeptin release in normo- to hyperosmolar states.

Time frame: beginning and end of protocol, up to 8 hours

Half life of Copeptin

Calculation of Copeptin half-life based on its decline during hypoosmotic suppression (oral waterload and glucose 5%-infusion)

Time frame: beginning and end of protocol, up to 8 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.